TSBX

Turnstone Biologics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 0

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About TSBX

Turnstone Biologics Corp.

A clinical stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors

Industry

Biological Technology

Established Date

12/13/2018

Listing Date

07/21/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.turnstonebio.com

Security Type

Common stock

Office address

9310 Athena Circle, Suite 300, La Jolla, California 92037

Business

Introduction

Turnstone Biologics Corp. was incorporated on December 13, 2018 under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on developing new drugs to treat and cure patients with solid tumors. The approved immunotherapy represents a significant advance in the treatment of solid tumors, but many patients either do not respond or experience disease recurrence after an initial response. The company believes that the most significant challenge in creating therapeutic immunotherapies in these patients is the low number of T cells that can recognize and attack tumors, which the company calls tumor-reactive T cells. To solve this problem, the company is pioneering a differentiated approach for tumor-infiltrating lymphocytes (TILs).

Company Financials

EPS

TSBX has released its 2024 Q4 earnings. EPS was reported at -0.56, versus the expected -0.87, beating expectations. The chart below visualizes how TSBX has performed over recent quarters, highlighting trends in earnings surprises.